Acceso usuarios
Abdulkareem A. Alanezi
Diabetes mellitus is a chronic metabolic disorder that affects millions of people worldwide, with its associated complications presenting significant challenges for both individuals and healthcare systems. Effective pharmacological management is essential for achieving optimal glycaemic control, which is key to preventing microvascular issues like retinopathy, nephropathy, and neuropathy, as well as macrovascular problems such as cardiovascular disease and stroke. Recent advancements in diabetes treatment have been driven by the introduction of novel drug classes, including sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagonlike peptide-1 (GLP-1) receptor agonists, which not only improve glycaemic control but also offer protective effects for the heart and kidneys. While traditional medications, like metformin, sulfonylureas, and insulin, continue to play a central role, their effectiveness is limited by potential side effects, such as hypoglycaemia and weight gain. Ground-breaking clinical trials, including DCCT, UKPDS, EMPA-REG OUTCOME, LEADER, and SONAR have demonstrated the critical link between pharmacological treatments and the reduction of diabetes-related complications. This review examines the current understanding of the mechanisms, effectiveness, and safety of antidiabetic medications, with a focus on their long-term benefits. It also explores emerging trends, such as personalized medicine, digital health innovations, and new therapeutic targets that aim to address remaining cardiovascular and microvascular risks. As the global burden of diabetes continues to rise, there is a pressing need for tailored pharmacological strategies, guided by evidence-based guidelines and individualized patient needs, to improve outcomes and quality of life. This review highlights the importance of ongoing innovation and collaborative efforts to tackle the complex challenges posed by diabetes and its complications.
